CDK4/6 inhibitors: taking the place of chemotherapy?
A partir d'une revue systématique de la littérature publiée entre 2000 et 2017 (140 essais de phase II et III, 50 029 patients), cette méta-analyse compare l'efficacité, du point de vue de la survie sans progression, des chimiothérapies et des hormonothérapies, dispensées avec ou sans thérapies ciblées, en traitement de première et seconde ligne chez des patientes ménopausées atteintes d'un cancer du sein HR+, HER2- de stade métastatique
The treatment landscape for advanced breast cancer has shifted dramatically over the past decade with the successive approvals of a multitude of targeted therapies. Specifically, CDK4/6 inhibitors have introduced a new treatment framework in the management of postmenopausal patients with hormone-receptor-positive, HER2-negative disease, who comprise the majority of patients with breast cancer. Clinical practice patterns have begun to veer away from a single-agent chemotherapy approach in the metastatic setting and towards upfront combination therapies with targeted agents in addition to endocrine therapy. Clearly delineating evidence, however, is needed to guide selection of one regimen over another in many cases.
The Lancet Oncology , commentaire, 2018